Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye

Inclusion criteria

• Age 18-70 years (inclusive), male or female;
• Subject reports dry eye symptoms for at least 6 months;
• Diagnosis of mild to moderate dry eye according to the Chinese Dry Eye Expert Consensus (2020) criteria:

• Mild dry eye: fluorescein tear film break-up time (FBUT) ≥2 seconds, no significant ocular surface damage signs, corneal fluorescein staining score <5;
• Moderate dry eye: FBUT ≥2 seconds AND corneal fluorescein staining dots <30 or not exceeding 2 quadrants;
• Normal tear secretion: Schirmer I test ≥10 mm/5 min;
• Daily electronic screen usage >6 hours;
• Electronic screen use for at least 5 days/week, for more than 1 year;
• Understands and provides written informed consent.

Exclusion criteria

• Allergy or hypersensitivity to any component of the study drugs;
• Requires the use of artificial tears (other than study drug), secretagogues, ocular surface repair agents, anti-inflammatory/antibiotic eye drops, or other dry eye-related drugs (e.g., muscarinic receptor blockers for visual fatigue) during the study period;
• Presence of any of the following ocular or systemic conditions:

• Active ocular infection, ocular inflammation, or active ocular allergy;
• Conjunctivochalasis, nasolacrimal duct obstruction;
• Glaucoma or elevated intraocular pressure;
• Retinal disease or ocular tumor;
• Requirement to wear contact lenses during the study;
• Obstructive sleep apnea syndrome or sleep disorders;
• Planned or ongoing physical therapy (intense pulsed light, meibomian gland massage, warm compress, thermopulsation) within 2 weeks before enrollment through the end of study;
• Ocular surgery within 3 months prior to enrollment, incomplete recovery from previous ocular surgery, or planned ophthalmic surgery during the study period;
• Current smoker;
• Pregnant or breastfeeding women, or women planning to become pregnant during the study period;
• Uncontrolled systemic disease, or use of systemic medications (e.g., beta-blockers, benzodiazepines, corticosteroids, antihistamines, or other medications that may interfere with tear production);
• History of anxiety or depression;
• Any other condition that, in the judgment of the investigator, would make the subject unsuitable for participation.